Uterine sarcoma: the possibility of modeling a rare tumor and providing its morphological description

Purpose of the study. To create a model of uterine sarcoma in female white mongrel rats and provide description of its morphological features.

Materials and methods. In the in vivo experiment, white mongrel female laboratory rats (n = 20) weighing 250 ± 25 g were used, and the M1 strain of rat sarcoma was used as an experimental tumor model. The studied groups of animals: Group 1 (n = 10) – administration of 0.5 ml of tumor suspension containing 2.5–3.5 × 106 cells using an intravenous catheter with an injection port 22G, 0.9 × 25 mm; group 2 (n = 10) – donors of tumor material with subcutaneous M1 grafting according to the standard method. Xylazine‑ zolethyl anesthesia was used during surgical interventions. The duration of the experiment was 21 days. After killing the animals, median longitudinal histological sections were made from the tumor node, 5–7 microns thick, stained with hematoxylin‑ eosin.

Results. Unlike subcutaneous grafting of sarcoma M1, the tumor growing in the uterine horn was characterized by the presence in the abdominal cavity of many nodules and tumor dropouts on the mesentery, i. e. lymph nodes. According to the cellular composition, tumors formed from a suspension of M1 sarcoma cells injected into the right horn of the uterus were characterized by a polymorphocellular type of structure against the background of pronounced neoangiogenesis. Necrosis and hemorrhages were noted in certain sections of the preparations with a polyp‑like tumor form, which corresponds to destructive signs of rapid growth and development of uterine sarcoma.

Conclusion. The possibility of modeling a relatively rare tumor by introducing a suspension of M1 sarcoma cells into the right uterine horn of female rats has been established. The nature of multinodular tumor growth with pronounced polymorphism of the cellular composition, areas of necrotization and hemorrhage demonstrates the adequacy of the uterine sarcoma model for the implementation of research tasks in clinical oncology.

1. Liu J, Wang Z. Advances in the Preoperative Identification of Uterine Sarcoma. Cancers (Basel). 2022 Jul 20;14(14):3517. doi: 10.3390/cancers14143517

2. He X, Dong Q, Weng C, Gu J, Yang Q, Yang G. Trends in incidence, survival and initial treatments of gynecological sarcoma: a retrospective analysis of the United States subpopulation. BMC Womens Health. 2023 Jan 9;23(1):10. doi: 10.1186/s12905‑023‑02161‑1

3. Mallmann P. Uterine Sarcoma ‑ Difficult to Diagnose, Hard to Treat. Oncol Res Treat. 2018;41(11):674. doi: 10.1159/000494393

4. Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma : A review of the literature and update on management options. Gynecol Oncol. 2018 Dec;151(3):562–572. doi: 10.1016/j.ygyno.2018.09.010

5. Arend R, Doneza JA, Wright JD. Uterine carcinosarcoma. Curr Opin Oncol. 2011 Sep;23(5):531–536. doi: 10.1097/CCO.0b013e328349a45b

6. Conklin CM, Longacre TA. Endometrial stromal tumors: the new WHO classification. Adv Anat Pathol. 2014 Nov;21(6):383–393. doi: 10.1097/pap.0000000000000046

7. Cotzia P, Benayed R, Mullaney K, Oliva E, Felix A, Ferreira J, et al. Undifferentiated Uterine Sarcomas Represent Under‑Recognized High‑grade Endometrial Stromal Sarcomas. Am J Surg Pathol. 2019 May;43(5):662–669. doi: 10.1097/pas.0000000000001215

8. Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine Adenosarcoma : a Review. Curr Oncol Rep. 2016 Nov;18(11):68. doi: 10.1007/s11912‑016‑0552‑7

9. Nechushkina VM, Kolomiets LA, Kravets OA, Morkhov KYu, Novikova EG, Novikova OV, et al. Uterine body cancer and uterine sarcomas. Malignant Tumoursis. 2023;13(3S2‑1):263–279. (In Russ.). doi: 10.18027/2224‑5057‑2023‑13‑3s2‑1‑263‑279

10. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small‑cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009 Apr 15;69(8):3364–3373. doi: 10.1158/0008‑5472.can‑08‑4210

11. Frantsiyants EM, Kaplieva IV, Bondovkina VA, Surikova EI, Neskubina IV, Trepitaki LK, et al. Modeling of multiple primary malignant tumors in experiment. South Russian Journal of Cancer. 2022;3(2):14–21. doi: 10.37748/2686‑9039‑2022‑3‑2‑2

12. Kit OI, Frantsiyants EM, Kaplieva IV, Surikova EI, Trepitaki LK, Neskubina IV, Lesovaya NS. A method for canceling genetically determined inhibition of malignant tumor grouth in an experiment. The patent for the invention RU 2718671 C1, 04/13/2020. Application № 2019124739 from 08/01/2019. (In Russ.).

13. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient‑derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012 Apr 17;9(6):338–350. doi: 10.1038/nrclinonc.2012.61

14. Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez‑Dunddel D, et al. Patient‑derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol. 2017 Oct 1;28(10):2595–2605. doi: 10.1093/annonc/mdx416

15. Moiola CP, Lopez‑Gil C, Cabrera S, Garcia A, Van Nyen T, Annibali D, et al. Patient‑Derived Xenograft Models for Endometrial Cancer Research. Int J Mol Sci. 2018 Aug 17;19(8):2431. doi: 10.3390/ijms19082431

16. Guerin MV, Finisguerra V, Van den Eynde BJ, Bercovici N, Trautmann A. Preclinical murine tumor models: a structural and functional perspective. Elife. 2020 Jan 28;9:e50740. doi: 10.7554/elife.50740

17. Pabiarzhyn VV, Pashinskaya ES, Semenov VM, Hancharou AY. Methodological aspects of setting up oncological models under experimental conditions. Vitebsk Medical Journal. 2018;17(6):32–45. (In Russ.). doi: 10.22263/2312‑4156.2018.6.32

18. Vollmer G. Endometrial cancer: experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocr Relat Cancer. 2003 Mar;10(1):23–42. doi: 10.1677/erc.0.0100023

19. Kawabe S, Mizutani T, Ishikane S, Martinez ME, Kiyono Y, Miura K, et al. Establishment and characterization of a novel orthotopic mouse model for human uterine sarcoma with different metastatic potentials. Cancer Lett. 2015 Oct 1;366(2):182–190. doi: 10.1016/j.canlet.2015.06.018

20. Cuppens T, Depreeuw J, Annibali D, Thomas D, Hermans E, Gommé E, et al. Establishment and characterization of uterine sarcoma and carcinosarcoma patient‑derived xenograft models. Gynecol Oncol. 2017 Sep;146(3):538–545. doi: 10.1016/j.ygyno.2017.06.005

21. Garcia N, Ulin M, Ali M, Al‑Hendy A, Carvalho KC, Yang Q. Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model. Reprod Sci. 2022 Mar;29(3):781–790. doi: 10.1007/s43032‑021‑00731‑y

22. Noh JJ, Cho YJ, Ryu JY, Choi JJ, Hwang JR, Choi JY, Lee JW. Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma. Clin Cancer Res. 2022 Sep 1;28(17):3850–3861. doi: 10.1158/1078‑0432.ccr‑22‑0985

23. Zhang W, Fan W, Rachagani S, Zhou Z, Lele SM, Batra SK, Garrison JC. Comparative Study of Subcutaneous and Orthotopic Mouse Models of Prostate Cancer: Vascular Perfusion, Vasculature Density, Hypoxic Burden and BB2r‑Targeting Efficacy. Sci Rep. 2019 Jul 31;9(1):11117. doi: 10.1038/s41598‑019‑47308‑z

24. Models and methods in experimental oncology. Edited by A.D. Timofeevsky. M.: "Medgiz";1960. (In Russ.).

25. Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:51–58. doi: 10.1002/ijgo.12613

26. Hoang L, Chiang S, Lee CH. Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations. Pathology. 2018 Feb;50(2):162–177. doi: 10.1016/j.pathol.2017.11.086

27. Lewis D, Liang A, Mason T, Ferriss JS. Current Treatment Options: Uterine Sarcoma. Curr Treat Options Oncol. 2024 Jul;25(7):829–853. doi: 10.1007/s11864‑024‑01214‑3

28. Frantsiyants EM, Shikhlyarova AI, Kaplieva IV, Bandovkina VA, Pogorelova YuA, Neskubina IV, et al. The method of creating a model of uterine sarcoma. The patent for the invention RU 2820404 C1, 03. 06. 2024. Application № 2024104813 from 27. 02. 2024 (In Russ.).